What factors affect calcitonin levels?
Calitonine is a hormone produced in the thyroid glands, bodies and parapholicular cells, also called C-cells, thyroid glands. The obvious function of this hormone is to reduce the amount of calcium in the blood and increase the deposits of calcium and phosphate in the bones, which is a positive force in maintaining bone density. Factors that may affect calcitonin levels include nutrition, age, sex and the presence of certain diseases. Tyroidal or thyroid removal is usually performed and radiation treatment may follow. After removal of the tumor, the patient will continue to have periodic tests to check calcitonin levels in the blood; If the level increases dramatically, it may indicate that the cancer has returned.
Increased levels of calcitonin also occur in the presence of bone cancer. These diseases interfere with the ability of bones to maintain calcium, which further accelerates the ability of cancer to metastasize bone mass. Doctors often give calcitonin derived from salmon through injections or nasal SPReji patients with bone cancer to raise calcitonin levels and slow bone loss.
Paget's disease causes the disintegration of the existing bone, which is replaced by new, weaker bones and sometimes results in deformity. Increased levels of phosphates in the blood may be an indication of paget and treatment may include calcitonin injections to increase blood calcitonin levels. Increased calcitonin helps bones to maintain more calcium and mass
Long -term flaws of calcium and vitamin D can also affect calcitonin levels, as bones and teeth do not receive sufficient calcium to maintain optimal and strength. If nutritional deficiencies are responsible for changes in calcitonin, doctors generally recommend calcium supplements and increased deficiencies of vitamin D can be repaired supplements or digestive time outside the absorbing natural vitamin D for sunlight through the skin.
/P>Age and gender are also factors in abnormal calcitonin levels, and some studies suggest that these changes in postmenopausal women may increase the likelihood of osteoporosis, which is the loss of bone density that makes bones more susceptible to fractures. While more studies need to be performed, postmenopausal women with osteoporosis that are treated with calcitonin have improved bone density. The FDA allowed calcitonine nasal spray to treat osteoporosis in women and patients with paget disease and those who have a condition called hypercalcaemia or high blood calcium.